According to a January 13th press release, Chr. Hansen increased revenue for the first quarter of Fiscal 2022 by 10 percent to $305 million.  Growth and revenue was driven by volume with the Core Business segment delivering a seven percent increase in organic growth, Food Cultures and Enzymes by seven percent and Health and Nutrition delivering 13 percent.  EBIT increased by seven percent to $74 million for the quarter with increased contributions by Health and Nutrition and Food Cultures and Enzymes. 

In commenting on results, Mauricio Graber, CEO, stated “Progress across all business areas and strategic initiatives underlines the strength of our 2025 strategy.  The encouraging start to the year with organic growth of nine percent and progress across all business and strategic areas and initiatives underlines the strength of our 2025 strategy differentiating us as a bioscience company focused on microbial and fermentation technology platforms.”

The Company confirmed guidance provided in October 2021 for the current fiscal year with organic growth expected in the range of five to eight percent and an EBIT margin of 27 to 28 percent with free cash flow before special items in the range of $160 to $190 million.